These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37218673)

  • 1. Amisulpride as a potential disease-modifying drug in the treatment of tauopathies.
    Jahreis K; Brüge A; Borsdorf S; Müller FE; Sun W; Jia S; Kang DM; Boesen N; Shin S; Lim S; Koroleva A; Satała G; Bojarski AJ; Rakuša E; Fink A; Doblhammer-Reiter G; Kim YK; Dityatev A; Ponimaskin E; Labus J
    Alzheimers Dement; 2023 Dec; 19(12):5482-5497. PubMed ID: 37218673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor.
    Labus J; Röhrs KF; Ackmann J; Varbanov H; Müller FE; Jia S; Jahreis K; Vollbrecht AL; Butzlaff M; Schill Y; Guseva D; Böhm K; Kaushik R; Bijata M; Marin P; Chaumont-Dubel S; Zeug A; Dityatev A; Ponimaskin E
    Prog Neurobiol; 2021 Feb; 197():101900. PubMed ID: 32841723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants for activation of the Tau kinase CDK5 by the serotonin receptor 5-HT7R.
    Ackmann J; Brüge A; Gotina L; Lim S; Jahreis K; Vollbrecht AL; Kim YK; Pae AN; Labus J; Ponimaskin E
    Cell Commun Signal; 2024 Apr; 22(1):233. PubMed ID: 38641599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration.
    García-León JA; Cabrera-Socorro A; Eggermont K; Swijsen A; Terryn J; Fazal R; Nami F; Ordovás L; Quiles A; Lluis F; Serneels L; Wierda K; Sierksma A; Kreir M; Pestana F; Van Damme P; De Strooper B; Thorrez L; Ebneth A; Verfaillie CM
    Alzheimers Dement; 2018 Oct; 14(10):1261-1280. PubMed ID: 30036493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
    Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
    J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride Decreases Tau Protein Hyperphosphorylation in the Brain of OXYS Rats.
    Molobekova CA; Kondaurova EM; Ilchibaeva TV; Rodnyy AY; Stefanova NA; Kolosova NG; Naumenko VS
    Curr Alzheimer Res; 2023; 20(7):496-505. PubMed ID: 37641989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathogenesis of the Tauopathies.
    Götz J; Halliday G; Nisbet RM
    Annu Rev Pathol; 2019 Jan; 14():239-261. PubMed ID: 30355155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and pathological heterogeneity of primary tauopathies.
    Chung DC; Roemer S; Petrucelli L; Dickson DW
    Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
    Langerscheidt F; Wied T; Al Kabbani MA; van Eimeren T; Wunderlich G; Zempel H
    J Neurol; 2024 Jun; 271(6):2992-3018. PubMed ID: 38554150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.
    Silva MC; Haggarty SJ
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine.
    Cranston AL; Kraev I; Stewart MG; Horsley D; Santos RX; Robinson L; Dreesen E; Armstrong P; Palliyil S; Harrington CR; Wischik CM; Riedel G
    Cell Signal; 2024 Sep; 121():111269. PubMed ID: 38909930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
    Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
    Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.
    Xia Y; Sorrentino ZA; Kim JD; Strang KH; Riffe CJ; Giasson BI
    J Biol Chem; 2019 Nov; 294(48):18488-18503. PubMed ID: 31653695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
    Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
    Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability.
    Silva MC; Cheng C; Mair W; Almeida S; Fong H; Biswas MHU; Zhang Z; Huang Y; Temple S; Coppola G; Geschwind DH; Karydas A; Miller BL; Kosik KS; Gao FB; Steen JA; Haggarty SJ
    Stem Cell Reports; 2016 Sep; 7(3):325-340. PubMed ID: 27594585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tau: Clinical trials and novel therapeutic approaches.
    VandeVrede L; Boxer AL; Polydoro M
    Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice.
    Kreilaus F; Przybyla M; Ittner L; Karl T
    Behav Brain Res; 2022 May; 425():113812. PubMed ID: 35202719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.
    Karch CM; Jeng AT; Goate AM
    J Biol Chem; 2012 Dec; 287(51):42751-62. PubMed ID: 23105105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontotemporal Dementia P301L Mutation Potentiates but Is Not Sufficient to Cause the Formation of Cytotoxic Fibrils of Tau.
    Wang KW; Zhang G; Kuo MH
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.